ZOTS Stock Overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$156.12 |
| 52 Week High | US$184.75 |
| 52 Week Low | US$137.08 |
| Beta | 0.85 |
| 1 Month Change | 0.19% |
| 3 Month Change | -12.64% |
| 1 Year Change | -7.07% |
| 3 Year Change | 9.63% |
| 5 Year Change | n/a |
| Change since IPO | 39.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZOTS | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 3.3% | -1.3% | 1.0% |
| 1Y | -7.1% | 5.9% | 4.6% |
Return vs Industry: ZOTS underperformed the Austrian Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: ZOTS underperformed the Austrian Market which returned 4.6% over the past year.
Price Volatility
| ZOTS volatility | |
|---|---|
| ZOTS Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.1% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: ZOTS has not had significant price volatility in the past 3 months.
Volatility Over Time: ZOTS's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 14,100 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZOTS fundamental statistics | |
|---|---|
| Market cap | €70.77b |
| Earnings (TTM) | €2.22b |
| Revenue (TTM) | €8.11b |
31.9x
P/E Ratio8.7x
P/S RatioIs ZOTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZOTS income statement (TTM) | |
|---|---|
| Revenue | US$8.73b |
| Cost of Revenue | US$2.61b |
| Gross Profit | US$6.12b |
| Other Expenses | US$3.73b |
| Earnings | US$2.39b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.24 |
| Gross Margin | 70.08% |
| Net Profit Margin | 27.38% |
| Debt/Equity Ratio | 131.0% |
How did ZOTS perform over the long term?
See historical performance and comparison